WO1991001742A1 - Biologically active compositions - Google Patents
Biologically active compositions Download PDFInfo
- Publication number
- WO1991001742A1 WO1991001742A1 PCT/GB1990/001182 GB9001182W WO9101742A1 WO 1991001742 A1 WO1991001742 A1 WO 1991001742A1 GB 9001182 W GB9001182 W GB 9001182W WO 9101742 A1 WO9101742 A1 WO 9101742A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- officinalis
- plant
- valeariana
- extract
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 38
- 241000196324 Embryophyta Species 0.000 claims abstract description 13
- 239000004615 ingredient Substances 0.000 claims abstract description 7
- 244000118350 Andrographis paniculata Species 0.000 claims abstract description 6
- 230000000840 anti-viral effect Effects 0.000 claims abstract description 4
- 230000002519 immonomodulatory effect Effects 0.000 claims abstract description 4
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 3
- 230000000118 anti-neoplastic effect Effects 0.000 claims abstract description 3
- 239000000843 powder Substances 0.000 claims description 15
- 239000004480 active ingredient Substances 0.000 claims description 9
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 8
- 240000007164 Salvia officinalis Species 0.000 claims description 6
- 235000002912 Salvia officinalis Nutrition 0.000 claims description 6
- 235000002020 sage Nutrition 0.000 claims description 6
- 239000000284 extract Substances 0.000 claims description 5
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 5
- 241000621079 Elymus caninus Species 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 235000001968 nicotinic acid Nutrition 0.000 claims description 4
- 239000011664 nicotinic acid Substances 0.000 claims description 4
- 229960003512 nicotinic acid Drugs 0.000 claims description 4
- 229940109850 royal jelly Drugs 0.000 claims description 4
- 229940088594 vitamin Drugs 0.000 claims description 4
- 235000013343 vitamin Nutrition 0.000 claims description 4
- 239000011782 vitamin Substances 0.000 claims description 4
- 229930003231 vitamin Natural products 0.000 claims description 4
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 3
- 241000700605 Viruses Species 0.000 claims description 3
- 239000005515 coenzyme Substances 0.000 claims description 3
- 239000000787 lecithin Substances 0.000 claims description 3
- 235000010445 lecithin Nutrition 0.000 claims description 3
- 229940067606 lecithin Drugs 0.000 claims description 3
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims description 3
- 229960004172 pyridoxine hydrochloride Drugs 0.000 claims description 3
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 claims description 3
- 239000011764 pyridoxine hydrochloride Substances 0.000 claims description 3
- 229960000984 tocofersolan Drugs 0.000 claims description 3
- 102000010911 Enzyme Precursors Human genes 0.000 claims description 2
- 108010062466 Enzyme Precursors Proteins 0.000 claims description 2
- 241001408890 Epilobium roseum Species 0.000 claims description 2
- 229940087168 alpha tocopherol Drugs 0.000 claims description 2
- 230000000975 bioactive effect Effects 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 239000002076 α-tocopherol Substances 0.000 claims description 2
- 235000004835 α-tocopherol Nutrition 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000035269 cancer or benign tumor Diseases 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 244000126014 Valeriana officinalis Species 0.000 description 6
- 235000013832 Valeriana officinalis Nutrition 0.000 description 6
- 235000016788 valerian Nutrition 0.000 description 6
- 241000725303 Human immunodeficiency virus Species 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 4
- 244000052616 bacterial pathogen Species 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 235000008160 pyridoxine Nutrition 0.000 description 2
- 239000011677 pyridoxine Substances 0.000 description 2
- 231100000041 toxicology testing Toxicity 0.000 description 2
- 229940011671 vitamin b6 Drugs 0.000 description 2
- 241000209136 Agropyron Species 0.000 description 1
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 description 1
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 1
- 229910001111 Fine metal Inorganic materials 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229910000514 dolomite Inorganic materials 0.000 description 1
- 239000010459 dolomite Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/84—Valerianaceae (Valerian family), e.g. valerian
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
Definitions
- the present invention provides biologically active compositions, notably anti-viral compositions, and in particular compositions effective against HIV.
- compositions of this invention are based on one or more active ingredients present in the plant Valeariana officinalis and/or Andrographis paniculata, especially active ingredients present in the roots of such plants.
- compositions of this invention are based on active ingredients present in dry comminuted roots of V ; _ officinalis and/or A. paniculata. If desired, the roots or other part of the plant can be subjected to an ethanol or aqueous extraction in conventional manner.
- compositions are preferably based on Valeariana officinalis, which ingredient preferably comprises 35 to 60 % of the composition, typically 40 to 50 % of the composition.
- compositions of this invention are non-toxic, and preferably take the form of compositions for oral administration, such as tablets, though other dosage forms are not precluded.
- the compositions can contain auxilliary components, such as enzyme precursors, coenzymes, and related bioactive compounds, for example ⁇ hymotripsinogen A, coenzyme Q 1Q , lecithin, alpha-tocopherol, vitamins, nicotini ⁇ acid, and/or pyridoxine hydrochloride.
- Royal jelly is another useful ingredient. Extracts of other plants may also be incorporated, for instance extracts of Epilobium roseum, Agropyron ⁇ aninum, and/or Salvi officinalis.
- compositions based on the active ingredients without necessarily obtaining these active ingredients from the plant sources. If the enzyme theory expressed below is substantiated, then the one or more enzymes can be adopted.
- Retrovirus like HIV can not reproduce without having access to DNA.
- the HIV-virus has to enter a cell in which it produces a DNA replica of its own RNA moiety.
- the active signal substance enters the protein shell of the virus infected cell and give orders which make the protein shell decompose. The remainder of the virus-infected cell will then be taken care of by the T-cells.
- compositions Apart from activity against HIV, the present compositions have a more general anti-viral activity and also have antineoplastic, antibacterial and immunomodulatory activity.
- the resulting mixture prepared in this manner is identified by us as NR-2, and was submitted for testing.
- Figure 1 shows the results of toxicity testing of the tablets at the various indicated dilutions.
- Figure 2 shows the results of related toxicity testing using cells infected with HIV.
- Figure 3 shows the results on testing at various dilutions on a human tumour cell line.
- Figure 4 shows the results on testing at various dilutions on a human melanoma cell line.
- Example 3 0.5g tablets. A normal dose is calculated to be 4 tablets per day.
- the test diagrams are the same for the tablets as for the powder of Example 1.
- Effective tablets can also be made by grinding the dried roots.
- the following ingredients are then particularly suitable:
- the Valeriana officinalis, o-tocopherol, and vitamins are pre-mixed, dried at 80 * C, ground to a powder, and then mixed with the other ingredients before tabletting in conventional manner.
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Compositions with anti-viral, antineoplastic, antibacterial and/or immunomodulatory activity include one or more ingredients obtained from the plant Valeariana officinalis and/or Andrographis paniculata.
Description
Biologically Active Compositions
BACKGROUND OF THE INVENTION
The present invention provides biologically active compositions, notably anti-viral compositions, and in particular compositions effective against HIV.
SUMMARY OF THE INVENTION
The compositions of this invention are based on one or more active ingredients present in the plant Valeariana officinalis and/or Andrographis paniculata, especially active ingredients present in the roots of such plants.
PREFERRED EMBODIMENTS
For ease of manufacture, the compositions of this invention are based on active ingredients present in dry comminuted roots of V;_ officinalis and/or A. paniculata. If desired, the roots or other part of the plant can be subjected to an ethanol or aqueous extraction in conventional manner.
The compositions are preferably based on Valeariana officinalis, which ingredient preferably comprises 35 to 60 % of the composition, typically 40 to 50 % of the composition.
The compositions of this invention are non-toxic, and preferably take the form of compositions for oral
administration, such as tablets, though other dosage forms are not precluded. Apart from one or more active ingredients originating from V^ officinalis and/or A. paniculata, the compositions can contain auxilliary components, such as enzyme precursors, coenzymes, and related bioactive compounds, for example σhymotripsinogen A, coenzyme Q1Q, lecithin, alpha-tocopherol, vitamins, nicotiniσ acid, and/or pyridoxine hydrochloride. Royal jelly is another useful ingredient. Extracts of other plants may also be incorporated, for instance extracts of Epilobium roseum, Agropyron σaninum, and/or Salvi officinalis.
Within the present invention it is also possible to prepare compositions based on the active ingredients without necessarily obtaining these active ingredients from the plant sources. If the enzyme theory expressed below is substantiated, then the one or more enzymes can be adopted.
Without being bound by theory, it is theorized that a Retrovirus like HIV can not reproduce without having access to DNA. The HIV-virus has to enter a cell in which it produces a DNA replica of its own RNA moiety. The active signal substance enters the protein shell of the virus infected cell and give orders which make the protein shell decompose. The remainder of the virus-infected cell will then be taken care of by the T-cells. By the catalysing process of the enzymes in the plant materials, with the enzymes which are in the protein shell of the infected virus cell, a completely selective process has takes which does not effect any other cells and which does not have nor need any toxic components at all.
Apart from activity against HIV, the present
compositions have a more general anti-viral activity and also have antineoplastic, antibacterial and immunomodulatory activity.
EXAMPLES OF THE INVENTION
The present invention is illustrated by the following non-limiting Examples.
Example 1
Take one part (weight) of Valeriana officinalis to seven parts of water.
Boil the mixture for five hours.
Filter the mixture through a fine metal filter.
Let the filtration liquid cool down completely then centrifuge it at 5000RPM for 15 minutes. Decant the clear content and let it dry at 95*C until it is almost dry. Lower the temperature to 70*C and let it dry completely. Then grind it to a fine powder.
For storage keep it in a dry and airtight container.
Take one part of Epilobilum roseum to seven parts of water.
Boil the mixture for five hours.
(Proceed exactly as under 1. above)
Take one part of Salvia officinalis to seven parts of water.
Boil the mixture for five hours.
(Proceed exactly as under 1. above)
Now mix the above powders 1-3 as follows (weight %)
Powder No. 1 Valeriana officinalis 48.6% Powder No. 2 Epilobilum roseum 11.0%
Powder No. 3 Salvia officinalis 1.1%
5. Mix well and then add the following:
Royal jelly 17.3%
Nicotinic Acid 11.0%
Pyridoxine Hydroσhloridum 11.0%
The resulting mixture prepared in this manner is identified by us as NR-2, and was submitted for testing.
The test results are illustrated by the accompanying figures. * *
DESCRIPTION OF THE DRAWINGS
Figure 1 shows the results of toxicity testing of the tablets at the various indicated dilutions.
Figure 2 shows the results of related toxicity testing using cells infected with HIV.
Figure 3 shows the results on testing at various dilutions on a human tumour cell line.
Figure 4 shows the results on testing at various dilutions on a human melanoma cell line.
Example 2
Take one part of Valeriana officinalis to seven parts of water.
Boil the mixture for five hours.
(Proceed exactly as under 1. above)
Boil the mixture for five hours. (Proceed exactly as under 1. above)
9. Take one part of Salvia officinalis to seven parts of water.
Boil the mixture for five hours. (Procees exactly as under 1. above)
10. Take one part of Agropyron caninum germs to seven • parts of water.
Heat the water to boiling and pour it over the Agropyron caninum germs.
Wait five minutes then filter the mixture. (For the rest proceed as under 1. above)
11. Now mix the above powders 7-10 as follows (weight %)
Powder No.7 Valeriana officinalis 45.0%
Powder No.8 Epilobilum roseum 10.0%
Powder No.9 Salvia officinalis 1.0%
Powder No.10 Agropyron caninum germs 9.0%
12. Mix well and then add the following:
Royal Jelly 16.0%
Nicotinic Acid 1.0%
Pyridoxine Hydrochloridum 1.0%
Sodium Carbonate 10.0%
Wheat Pulp 4.0%
Magnesium Stearate 3.0%
13. The mix is then fed to a tablet machine to press
0.5g tablets. A normal dose is calculated to be 4 tablets per day. The test diagrams are the same for the tablets as for the powder of Example 1.
Example 3
Effective tablets can also be made by grinding the dried roots. The following ingredients are then particularly suitable:
(%)
Valeriana officinalis 45
Lecithin 4
Salvia officinalis 4
DL-α-tocopherol 1
A-D vitamins 1 pyridoxine hydrochloride 1 nicotinic acid 1 dolomite powder 5 flavouring 2 magnesium stearate 1.5 lactose 34.5
The Valeriana officinalis, o-tocopherol, and vitamins are pre-mixed, dried at 80*C, ground to a powder, and then mixed with the other ingredients before tabletting in conventional manner.
Claims
1. A composition effective against HIV, including one or more active ingredients present in the plant Valeariana officinalis and/or Andrographis paniculata.
2. The composition of claim 1, wherein the active ingredient is taken from the root of the plant.
3. The composition of claim 1, wherein the plant is Valeariana officinalis.
4. The composition of claim 1, wherein the active ingredient is employed as a dry powder obtained after aqueous extraction of the plant.
5. The composition of claim 1, in the form of a powder or a tablet.
6. The composition of claim 1, which further contains at least one auxiliary material chosen from enzyme precursors, coenzymes, and related bioactive compounds,- for example chymotripsinogen A, coenzy e Q10. lecithin, alpha-tocopherol, vitamins, nicotinic acid, and/or pyridoxine hydrochloride; royal jelly; an extract of Epilobium roseum; an extract of Agropyron caninum; and/or an extract of Salvia officinalis.
7. A composition with anti-viral, antineoplastic, antibacterial and/or immunomodulatory activity, which includes one or more ingredients obtained from the plant Valeariana officinalis and/or Andrographis paniculata.
8. A method for combatting a virus, neoplasm, or bacterium, or a method of immunomodulation, which employs a composition which includes one or more ingredients obtained from the plant Valeariana officinalis and/or Androqraphis paniculata.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB8917295.1 | 1989-07-28 | ||
| GB898917295A GB8917295D0 (en) | 1989-07-28 | 1989-07-28 | Anti-viral compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1991001742A1 true WO1991001742A1 (en) | 1991-02-21 |
Family
ID=10660788
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/GB1990/001182 WO1991001742A1 (en) | 1989-07-28 | 1990-07-30 | Biologically active compositions |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU6272490A (en) |
| GB (1) | GB8917295D0 (en) |
| WO (1) | WO1991001742A1 (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996017605A1 (en) * | 1994-12-06 | 1996-06-13 | Paracelsian, Inc. | Use of andrographolide compounds to treat or prevent pathogenicity of diseases |
| WO1999033866A3 (en) * | 1997-12-27 | 1999-09-10 | Gsf Forschungszentrum Umwelt | Antivirally active oligopeptide isolated from royal jelly |
| WO2001085710A1 (en) * | 2000-05-05 | 2001-11-15 | Dr. Reddy's Research Foundation | Novel anticancer compounds: process for their preparation and pharmaceutical compositions containing them |
| US6410590B1 (en) | 2000-02-03 | 2002-06-25 | Dr. Reddy's Research Foundation | Compounds having antitumor activity: process for their preparation and pharmaceutical compositions containing them |
| US6486196B2 (en) | 2000-05-05 | 2002-11-26 | Dr. Reddy's Research Foundation | Anticancer compounds: process for their preparation and pharmaceutical compositions containing them |
| US6576662B2 (en) | 2000-05-05 | 2003-06-10 | Dr. Reddy's Laboratories Limited | Compounds having anticancer activity : process for their preparation and pharmaceutical compositions containing them |
| US7135164B2 (en) * | 2001-11-09 | 2006-11-14 | Mahidol University | Andrographis paniculata gel as an adjunct in the treatment of periodontitis |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE149731C (en) * | 1902-11-20 |
-
1989
- 1989-07-28 GB GB898917295A patent/GB8917295D0/en active Pending
-
1990
- 1990-07-30 WO PCT/GB1990/001182 patent/WO1991001742A1/en unknown
- 1990-07-30 AU AU62724/90A patent/AU6272490A/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE149731C (en) * | 1902-11-20 |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996017605A1 (en) * | 1994-12-06 | 1996-06-13 | Paracelsian, Inc. | Use of andrographolide compounds to treat or prevent pathogenicity of diseases |
| WO1999033866A3 (en) * | 1997-12-27 | 1999-09-10 | Gsf Forschungszentrum Umwelt | Antivirally active oligopeptide isolated from royal jelly |
| US6410590B1 (en) | 2000-02-03 | 2002-06-25 | Dr. Reddy's Research Foundation | Compounds having antitumor activity: process for their preparation and pharmaceutical compositions containing them |
| WO2001085710A1 (en) * | 2000-05-05 | 2001-11-15 | Dr. Reddy's Research Foundation | Novel anticancer compounds: process for their preparation and pharmaceutical compositions containing them |
| US6486196B2 (en) | 2000-05-05 | 2002-11-26 | Dr. Reddy's Research Foundation | Anticancer compounds: process for their preparation and pharmaceutical compositions containing them |
| US6576662B2 (en) | 2000-05-05 | 2003-06-10 | Dr. Reddy's Laboratories Limited | Compounds having anticancer activity : process for their preparation and pharmaceutical compositions containing them |
| US7135164B2 (en) * | 2001-11-09 | 2006-11-14 | Mahidol University | Andrographis paniculata gel as an adjunct in the treatment of periodontitis |
Also Published As
| Publication number | Publication date |
|---|---|
| GB8917295D0 (en) | 1989-09-13 |
| AU6272490A (en) | 1991-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO1991001742A1 (en) | Biologically active compositions | |
| US4466960A (en) | Analgesic-diuretic compositions | |
| WO2021109511A1 (en) | Anti-fatigue composition and preparation method therefor | |
| JPH0358939A (en) | Aging preventive food agent and production thereof | |
| JPH04243832A (en) | Treating agent for autoimmune disease | |
| RU2000120474A (en) | PHARMACEUTICAL COMPOSITION POSSESSING ANTITUM ACTIVITY AND METHOD FOR PRODUCING IT | |
| CN103566282B (en) | A kind of Traditional Chinese medicine composition with anti-tumor effect and preparation method | |
| CA2248092A1 (en) | Harpagoside-enriched extract from harpagophytum procumbens and processes for producing same | |
| US6162438A (en) | Herbal compositions and their use as agents for control of hypertension, hypercholesterolemia and hyperlipidemia | |
| CN104127449A (en) | Combined ganoderma lucidum capsule for auxiliary inhibition on tumor and preparation method thereof | |
| JP2002205949A (en) | Method for ameliorating dysbolism and composition therefor | |
| JP2525484B2 (en) | Osteoporosis treatment | |
| WO1994018993A1 (en) | Therapeutic herbal composition | |
| JPH09208479A (en) | Salicaceae plant mixture | |
| JPS58172320A (en) | Antihyperlipidemic agent and its manufacturing method | |
| CN109419847A (en) | A kind of fresh leonurus Radix Notoginseng Chinese medicine composition and preparation method thereof | |
| WO1994018994A1 (en) | Therapeutic herbal composition | |
| JP2905911B2 (en) | Agent for suppressing or increasing the number of helper T cells in AIDS | |
| KR100977583B1 (en) | Extracting Caffeic Acid with Hepatocellular Protection and Hepatic Damage Prevention Effect in Firewood and Functional Health-Oriented Foods Comprising the Same | |
| RU2274400C1 (en) | Spotted milk thistle-base biologically active supplement for decreasing alcoholic dependence | |
| JP7162357B2 (en) | Absorption accelerator for cinnamic acid derivatives | |
| KR20030089253A (en) | A composition with enhanced immunomodulation and anti-cancer activity | |
| JPS61194031A (en) | Agent for promoting carcinostatic activity | |
| US7160561B2 (en) | Herbal composition and method of treating HIV infection | |
| EP0631785A1 (en) | Mineral ion solution, anti-human immunodeficiency virus agent, and aids-treating agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AT AU BB BG BR CA CH DE DK ES FI GB HU JP KP KR LK LU MC MG MW NL NO RO SD SE SU US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE BF BJ CF CG CH CM DE DK ES FR GA GB IT LU ML MR NL SE SN TD TG |
|
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| NENP | Non-entry into the national phase in: |
Ref country code: CA |